PDCD1 and neoplasm: The combination of MDZ and the PD-1 mAb is beneficial for increasing antitumor activity, which may provide novel clinical immunotherapeutic approaches for treating HCC and provide new evidence of the relationship between perioperative anaesthesia and HCC tumour progression.